Table 1.

Model Inputs to Evaluate 8 vs 12 Weeks of Treatment of HCV Genotype 1

Input	Value	Sensitivity Range Evaluated	Source
Cohort characteristics
Mean age	53	30–65	[12]
Proportion male, %	60	0–100	[12]
Average age at HCV infection	26	16–36	[27]
HCV disease progression
Median y to cirrhosis from infection	25	15–35	[28], [29]
Median y to first liver- related event after cirrhosis	11	6–17	[30]
Liver-related mortality with compensated cirrhosis, deaths/100 PY	1.4	0.7–2.8	[30]
Liver-related mortality with decompensated cirrhosis, deaths/100 PY	12	6–24	[30]
Reduction in liver mortality after SVR, %	94	81–98	[31]
HCV therapy efficacy, %
SVR of 8-wk regimen LDV/ SOF in black patients	96.3	72–100	[12]
SVR of 8-wk regimen LDV/ SOF in nonblack patients	96.9	72–100	[12]
SVR of 12-wk regimen LDV/ SOF in black patients	98.9	72–100	[12]
SVR of 12-wk regimen LDV/ SOF in nonblack patients	97.1	72–100	[12]
SVR of 12-wk regimen sofosbuvir/velpatasvir/ voxilaprevir	97.3	0–100	[32]
Retention to salvage treatment, %	24	0–100	[13]
Costs
Non-HCV-related medical costs, $ per mo
Background medical costs (without HCV)	110–1100	55–1650	[33]
Laboratory testing costs, $
IL28B genotype test	68.52	0–200	[34]
NS5A test	231.23	0–400	[34]
HCV related medical costs, $ per mo
No cirrhosis	245	185–305	[35]
Mild to moderate cirrhosis	440	315–550	[35]
Decompensated cirrhosis	830	620–1050	[35]
HCV therapy, $ per 4 wk
LDV/SOF	18900	9000–28 000	[23]
Sofosbuvir/velpatasvir/ voxilaprevir	18654	11 250–33 750	[23]
Quality of life
After achieving SVR	0.74–0.92	0.60–1	[36], [37]
No to moderate fibrosis	0.89	0.75–1	38–40]
Cirrhosis	0.62	0.55–0.75	[38], [39]
Decompensated cirrhosis	0.48	0.40–0.60	[38], [39]